Allecra Seeks US Partnership For Urinary Tract Asset As Regulatory Filings Approach
Following EU And China Deals
• By Ayisha Sharma
The French firm is searching for a US partner with strong foundations in the hospital sector after securing EU and China deals for its complicated urinary tract infection candidate that combines cefepime and enmetazobactam, which is nearing regulatory submission in key markets.
Allecra Is Teaming Up With Firms Across The Major Geographical Markets • Source: Shutterstock
Allecra Therapeutics GmbH is on the hunt for a commercialization partner across the Atlantic for its complicated urinary tract infection (cUTI) asset as it prepares imminent filings for the EU and US regulators.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.
